Developing a novel single dose prime-boost vaccine against malaria

This novel platform is based on the technological advance of the production of microcapsules from biodegradable polymers, which can act as vehicles into which the vaccine can be incorporated and then subsequently released in a delayed fashion. After achieving the optimal conditions for the microcapsules and the encapsulated vaccine, the aim is to mix the unencapsulated vaccine with the encapsulated booster vaccine dose and then administer both as a single injection. The new methodology will be tested with our current candidate malaria vaccine regime of heterologous immunisation using different viral vectors as a proof of concept. Using this approach, the vaccine delivery efficiency would be optimised by reducing the number of doses required from multiple into a single dose immunisation regime. Reducing the number of repeated injections would mean reduced costs, fewer clinic visits, and a higher compliance rate among vaccinees. A successful single-dose formulation could provide strong evidence for the initiation of clinical trials of the new technology with considerable benefits for future vaccine development.

Basic Science
Vaccines

Oct 2012 — Apr 2017

$322,318

United Kingdom